Thyroid nodule
Conditions
Interventions
Control Group:Basic treatment: Refer to the 2025 'Expert Consensus on Thyroid Nodule Risk Assessment and Health Management for Physical Examination Populations' for patient education about thyroid nod
Treatment group:Basic treatment + Nodule Formula: Basic treatment: Same as control group. Nodule Formula: Astragalus 30g, Processed Polygonum Multiflorum 12g, Zedoary 9g, Prunella Vulgaris 15g, Bergam
Sponsors
Shanghai University of Traditional Chinese Medicine Affiliated Yueyang Integrated Chinese and Western Medicine Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: (1) Age =18 years and =70 years, gender unrestricted; (2) First diagnosed during the initial visit, meeting the diagnostic criteria for thyroid nodules as per the "Guidelines for the Diagnosis and Treatment of Thyroid Nodules and Differentiated Thyroid Cancer" (TI-RADS classification =4a level); (3) Chinese medical syndrome differentiation belongs to phlegm Qi stagnation syndrome; (4) Maximum diameter of the nodule =10mm and =30mm; (5) Thyroid function and antibodies are within normal ranges; (6) Understanding, agreement to participate in this study, and signing of the informed consent form.
Exclusion criteria
Exclusion criteria: (1) Patients with nodules that have a possibility of malignancy as indicated by examination; (2) Patients who have taken other medications for thyroid nodules or undergone thyroid surgery or iodine-131 therapy within the past year; (3) Patients with other severe underlying diseases (such as impaired heart, liver, or kidney function, malignant tumors, etc.); (4) Pregnant or breastfeeding women, or women planning to conceive within the next year; (5) Patients with long-term alcohol abuse, drug dependence, or mental illness; (6) Patients with a known allergy to the investigational drug or any of its components; (7) Patients who have participated in or are currently participating in other clinical studies within the past month; (8) Patients deemed unsuitable for participation in this clinical study by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Thyroid Nodule Volume; | — |
Secondary
| Measure | Time frame |
|---|---|
| Maximum Diameter of Largest Thyroid Nodule;TCM Syndrome Score;Quality of Life Rating; | — |
Countries
China
Contacts
Public ContactYang Hongjie
Shanghai University of Traditional Chinese Medicine Affiliated Yueyang Integrated Chinese and Western Medicine Hospital
Outcome results
None listed